Clinical Study
Volumetric Modulated Arc Therapy of the Pelvic Lymph Nodes to the Aortic Bifurcation in Higher Risk Prostate Cancer: Early Toxicity Outcomes
Table 4
Tumour characteristics: RP cohort (
).
| | T stage | (%) | Gleason score at margin | (%) |
| | T1-2a | 20 (32%) | 3 | 7 (11%) | | T2b | 1 (1%) | 4 | 17 (27%) | | T2c-4 | 37 (59%) | 5 | 2 (3%) | | Unknown | 5 (8%) | Unknown | 37 (59%) |
| | Nodal status | (%) | Seminal vesicle involvement | (%) |
| | Negative | 44 (70%) | No | 41 (65%) | | Positive | 9 (14%) | Unilateral | 11 (17%) | | Unknown | 10 (16%) | Bilateral | 5 (8%) | | | | Unknown | 6 (10%) |
| | Gleason score | (%) | Vascular space involvement | (%) |
| | 7 | 29 (46%) | No | 40 (63%) | | 8 | 11 (17%) | Yes | 15 (24%) | | 9 | 20 (32%) | Unknown | 8 (13%) | | Unknown | 3 (5%) | | |
| | D’Amico Risk Group | (%) | Perineural involvement | (%) |
| | Intermediate | 31 (49%) | No | 36 (57%) | | High | 29 (46%) | Yes | 17 (27%) | | Unknown | 3 (5%) | Unknown | 10 (16%) |
| | Extracapsular extension | (%) | Lymph node dissection (LND) | (%) |
| | Absent | 19 (30%) | No | 25 (40%) | | Present | 41 (65%) | Yes | 37 (59%) | | Unknown | 3 (5%) | N/A or unknown | 1 (1%) |
| | Positive margin | (%) | Extended LND | (%) |
| | Absent | 34 (54%) | No | 20 (32%) | | Present | 27 (43%) | Yes | 22 (35%) | | Unknown | 2 (3%) | Unknown | 21 (33%) |
|
|
